Journal article

Epigenetic evidence of an Ac/Dc axis by VPA and SAHA

Sebastian Lunke, Scott Maxwell, Ishant Khurana, KN Harikrishnan, Jun Okabe, Keith Al-Hasani, Assam El-Osta

Clinical Epigenetics | BMC | Published : 2021


BACKGROUND: Valproic acid (VPA) is one of the most commonly used anti-epileptic drugs with pharmacological actions on GABA and blocking voltage-gated ion channels. VPA also inhibits histone deacetylase (HDAC) activity. Suberoylanilide hydroxamic acid is also a member of a larger class of compounds that inhibit HDACs. At the time of this article, there are 123 active international clinical trials for VPA (also known as valproate, convulex, divalproex, and depakote) and SAHA (vorinostat, zolinza). While it is well known that VPA and SAHA influence the accumulation of acetylated lysine residues on histones, their true epigenetic complexity remains poorly understood. RESULTS: Primary human cells..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC)

Funding Acknowledgements

Sam El-Osta is a National Health and Medical Research Council (NHMRC) Senior Research Fellow (1154650).